Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 6OTHER_GOV 2NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 4Breast 4Genitourinary 3Other 2Gastrointestinal 2Classical hematology 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Ovarian Neoplasms 1006Uterine Cervical Neoplasms 420Endometrial Neoplasms 350Carcinoma, Non-Small-Cell Lung 292Breast Neoplasms 292Neoplasms 238Colorectal Neoplasms 233Fallopian Tube Neoplasms 211Stomach Neoplasms 192Pancreatic Neoplasms 184Melanoma 157Prostatic Neoplasms 152Triple Negative Breast Neoplasms 148Carcinoma, Ovarian Epithelial 147Lung Neoplasms 136Neoplasm Metastasis 133Squamous Cell Carcinoma of Head and Neck 131Carcinoma, Renal Cell 130Head and Neck Neoplasms 122Esophageal Neoplasms 121Urinary Bladder Neoplasms 112Small Cell Lung Carcinoma 90Sarcoma 80Carcinoma, Hepatocellular 76Recurrence 70Carcinoma, Transitional Cell 70Uterine Cervical Dysplasia 66Papillomavirus Infections 66Colonic Neoplasms 59Cholangiocarcinoma 59

Interventions

sagopilone 1allantoicase 1Prednisolone 1BID protein, human 1Acetylcarnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peripheral Nervous System Diseases × Gynecologic × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡